Rami Komrokji, MD, of the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the importance of identifying patients with lowrisk myelodysplastic syndromes (MDS) using the Revised International Prognostic Scoring System (IPSSR) and mutation testing, before outlining the optimal treatment strategy for MDS. Dr Komrokji talks on the initial treatment options available for symptomatic anemia and for those with thrombocytopenia, focusing on the use of erythropoietinstimulating agents (ESAs) which have been shown to work well for patients with low transfusion burdens. Dr Komrokji also discusses the treatment options available for the MDS subtype, del(5q), and how patients may further benefit from the immunomodulatory drug lenalidomide, before talking on the use of luspatercept for patients with SF3B1, highlighting data from the COMMANDS trial (NCT03682536). This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.